SEARCH:   Advanced

Blood, 4 June 2009, Vol. 113, No. 23, pp. 6011-6014. Prepublished online as a Blood First Edition Paper on March 23, 2009; DOI 10.1182/blood-2008-12-195388. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-12-195388v1 113/23/6011    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Díez-Martín, J. L. Articles by Sureda, A. PubMed PubMed Citation Articles by Díez-Martín, J. L. Articles by Sureda, A. Related Collections Immunobiology Transplantation Free Research Articles Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief report Comparable survival between HIV+ and HIV– non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation José L. Díez-Martín1,*, Pascual Balsalobre1,*, Alessandro Re2, Mariagrazia Michieli3, José M. Ribera4, Carmen Canals5, Eulogio Conde6, Anne Rosselet7, Ian Gabriel8, Rosario Varela9, Bernardino Allione10, Kate Cwynarski11, Philippe Genet12, Ildefonso Espigado13, Pierre Biron14, Norbert Schmitz15, Anne E. Hunter16, Augustin Ferrant17, Gaelle Guillerm18, Mark Hentrich19, Manuel Jurado20, Pascual Fernández21, David Serrano22, Giuseppe Rossi2, Anna Sureda23, on behalf of the European Group for Blood and Marrow Transplantation Lymphoma Working Party 1 Hematology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain; 2 Hematology Department, Spedali Civili, Brescia, Italy; 3 High Dose Chemotherapy and Cellular Therapies Unit, Centro di Riferimento Oncologico, Aviano, Italy; 4 Clinical Hematology, Institut Catalá d'Oncologia-Hospital Universitario German Trias i Pujol, Badalona, Spain; 5 Biostatistics, European Group for Blood and Marrow Transplantation Lymphoma Working Party, Barcelona, Spain; 6 Hematology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain; 7 Hematology Department, Centre Hospitalier Universitaire Vaudois, Lausane, Switzerland; 8 Hematology Department, Hammersmith Hospital, London, United Kingdom; 9 Hematology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; 10 Hematology Department, Ospedale Santo Antonio e Biagio, Alessandria, Italy; 11 Hematology Department, Royal Free Hospital, London, United Kingdom; 12 Hematology Department, Hopital Victor Dupouy, Argenteuil, France; 13 Hematology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain; 14 Hematology Department, Centre Leon Berard, Lyon, France; 15 Hematology Department, Asklepios Klinik St. Georg, Hamburg, Germany; 16 Hematology Department, Leicester Royal Infirmary, Leicester, United Kingdom; 17 Hematology Department, Cliniques Universitaires St Luc, Brussels, Belgium; 18 Hematology Department, Hopital Augustin-Morvan, Brest, France; 19 Hematology Department, Klinikum Harlaching, Munich, Germany; 20 Hematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain; 21 Hematology Department, Hospital General Alicante, Alicante, Spain; 22 Hematology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain; and 23 European Group for Blood and Marrow Transplantation Lymphoma Working Party, Barcelona, Spain Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy. We report the first comparative analysis between HIV-Ly and a matched cohort of HIV– lymphoma patients. This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort. Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort. Incidence of relapse, overall survival, and progression-free survival were similar in both cohorts. A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival. Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV– lymphoma patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Hentrich, X. Schiel, A. Niedermeier, L. Lutz, R. Rupec, C. Stief, J. Bogner, M. Karthaus, and A. Gerl Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor Ann. Onc., November 1, 2009; 20(11): 1900 - 1901. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020